Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Gastroenterology|October 16, 2013
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapyNezam H Afdhal, Geoffrey M Dusheiko, Edoardo G Giannini, et al.
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Pageof 16